Author's response to 'Surfactant administration during endotracheal CPAP-Is DD-SURF comparable to LISA?'
- PMID: 37166439
- DOI: 10.1111/apa.16840
Author's response to 'Surfactant administration during endotracheal CPAP-Is DD-SURF comparable to LISA?'
Comment on
-
Surfactant administration during endotracheal CPAP-Is DD-Surf comparable to LISA?Acta Paediatr. 2023 Aug;112(8):1808-1809. doi: 10.1111/apa.16834. Epub 2023 May 17. Acta Paediatr. 2023. PMID: 37163241 No abstract available.
References
REFERENCES
-
- Mense L, Hansmann T, Seipolt B, Kaufmann M, Rüdiger M. Surfactant administration during endotracheal CPAP: feasibility, risk factors for failure and short-term outcomes of DD-SURF. Acta Paediatr. 2023;112(8):1653-1658. http://www.ncbi.nlm.nih.gov/pubmed/36946356
-
- Khurana S. Surfactant administration during endotracheal CPAP-Is DD-SURF comparable to LISA? Acta Paediatr. 2023;112(8):1808-1809. doi:10.1111/apa.16834
-
- Waitz M, Engel C, Schloesser R, et al. Application of two different nasal CPAP levels for the treatment of respiratory distress syndrome in preterm infants-"The OPTTIMMAL-Trial"-optimizing PEEP To The IMMAture Lungs: study protocol of a randomized controlled trial. Trials. 2020;21:822.
-
- Rüdiger M, Rozycki HJ. It's time to reevaluate the Apgar score. JAMA Pediatr. 2020;174:321-322. https://pubmed.ncbi.nlm.nih.gov/32091567/
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources